XELJANZ (tofacitinib) ( DrugBank: Tofacitinib )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 65 | Primary immunodeficiency | 1 |
65. Primary immunodeficiency
Clinical trials : 482 / Drugs : 653 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 212
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05104723 (ClinicalTrials.gov) | March 24, 2022 | 2/11/2021 | Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications | A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications | Chronic Granulomatous Disease;Inflammatory Gastrointestinal Disease;Inflammatory Skin Disease;Inflammatory Lung Disease | Drug: XELJANZ (tofacitinib) | National Institute of Allergy and Infectious Diseases (NIAID) | NULL | Enrolling by invitation | 18 Years | N/A | All | 20 | Phase 1/Phase 2 | United States |